Semaglutide for heart outcomes in adults with type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 to 49
- Have type 1 diabetes, confirmed by specific antibodies or a diagnosis plus insulin needed since diagnosis
- Use an insulin pump or an automated insulin delivery system
- Kidney function must be in a safe range (eGFR at least 45)
- Have a body mass index (BMI) between 20 and 45
- Use birth control if you can get pregnant, and not be pregnant or nursing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests semaglutide (a diabetes and weight-related medicine) to see if it can slow or improve diabetic kidney disease in people with type 1 diabetes. You may be able to join if you have type 1 diabetes for at least 5 years and ongoing signs of kidney damage measured in urine tests.
This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.
This trial studies whether the drug semaglutide can help people with heart failure who are overweight. It aims to see if the drug improves heart function and symptoms.
This study tests whether the diabetes medication semaglutide can reduce inflammation and improve blood vessel health in people with type 2 diabetes who have no significant heart artery blockages. If you have diabetes and are at moderate to high heart risk but haven't had heart problems, this could help understand the medicine's extra benefits beyond blood sugar control.
This trial tests whether adding a weekly semaglutide injection (a GLP-1 drug) to a closed-loop insulin system can help reduce the need for carb counting in people with type 1 diabetes. It aims to improve blood sugar control and make diabetes management easier.
This trial tests if adding semaglutide and empagliflozin to your automated insulin delivery system (like a smart pump) can improve blood sugar control for adults with type 1 diabetes. It may help with both glucose levels and weight management.
Hear when a new Diabetes Mellitus, Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.